Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phago-Staph
- Development stage
- Unknown
- Lead developer
- Eliava Biopreparations
- Modality
- Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral, Topical, Injection, Inhalation
01
Overview
Phago-Staph is a bacteriophage preparation developed by the G. Eliava Institute of Bacteriophages, Microbiology and Virology and manufactured by Eliava Biopreparations. It consists of a purified phage lysate specifically designed to target and lyse Staphylococcus aureus bacterial strains. As a biological therapeutic, it is used for the treatment and prophylaxis of a wide range of staphylococcal infections, including respiratory, surgical, urogenital, and enteric infections, as well as purulent-septic conditions in newborns. The preparation is administered via multiple routes such as oral, topical, injection, and nebulization, providing a targeted alternative or adjunct to traditional antibiotic therapy.
- Brand names
- Phago-Staph
- Other names
- Staphylococcal bacteriophageStaphylococcus bacteriophage
02
Targets
SpA (Staphylococcal protein A)
Beyond the preview
Go deeper on Phago-Staph.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Phago-Staph.